HDAC9 and glioblastoma: The non-specific inhibitor Vorinostat surprisingly promoted migration in the cells at its 2D IC50 value treatment, and none of the inhibitors was able to significantly decrease late resistance compared to untreated controls, indicating the need for the development of more potent HDAC inhibitors for monotherapy for GBM.